Contineum Therapeutics (NASDAQ:CTNM) Releases Earnings Results, Beats Expectations By $0.01 EPS

Contineum Therapeutics (NASDAQ:CTNM) posted its quarterly earnings data on Wednesday. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.01, Zacks reports.

Contineum Therapeutics Trading Down 0.8 %

Shares of NASDAQ CTNM traded down $0.15 during trading hours on Friday, hitting $18.40. The company had a trading volume of 44,394 shares, compared to its average volume of 73,289. Contineum Therapeutics has a 1-year low of $13.27 and a 1-year high of $22.00. The firm’s 50 day moving average is $17.58 and its 200-day moving average is $17.77.

Analysts Set New Price Targets

A number of equities analysts have weighed in on CTNM shares. Robert W. Baird assumed coverage on Contineum Therapeutics in a research report on Tuesday, October 22nd. They set an “outperform” rating and a $32.00 price target for the company. Royal Bank of Canada reduced their target price on shares of Contineum Therapeutics from $32.00 to $31.00 and set an “outperform” rating for the company in a report on Thursday. Finally, Baird R W upgraded shares of Contineum Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 22nd. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Contineum Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $29.25.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).